Publications by authors named "Wallman J"
Article Synopsis
- - The research aimed to assess data collection practices for non-musculoskeletal manifestations (NMMs), comorbidities, and safety outcomes in patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) across 17 European registries, emphasizing the need for international collaboration for better treatment strategies.
- - A comprehensive survey with over 4,400 questionnaire items examined how 58 defined conditions were recorded in each registry, focusing on recording methods and the ability to link data to national registries.
- - The study found that while many registries recorded a variety of conditions consistently, Nordic countries showed potential for data linkage but had limited recording practices, while other regions maintained thorough documentation, paving the way
Article Synopsis
- The study aimed to evaluate the retention rates and remission outcomes of patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who started treatment with secukinumab over 24 and 48 months.
- Data was collected from 13 European registries, revealing that retention rates were around 51%-64%, and patients with no prior biologic treatments showed better outcomes compared to those with previous treatments.
- The findings suggest that secukinumab remains effective over four years, with higher success rates in treatment-naïve patients compared to those who had already tried other therapies.
Blowfly genomics: current insights, knowledge gaps, and future perspectives.
Curr Opin Insect Sci
November 2024
Article Synopsis
- - Blowflies are a diverse group with limited genomic information available, as only 16 species have publicly accessible genome assemblies, despite there being many more species known.
- - The current genetic databases show significant gaps, with only about 16.5% of blowfly species represented in DNA barcodes, approximately 3% in mitogenomes, and less than 1% in complete genomes.
- - The review emphasizes the need for more comprehensive genomic research across various blowfly subfamilies to improve studies related to their identification, evolution, and systematics.
Objectives: To re-evaluate cut-offs for disease activity states according to the Axial Spondyloarthritis Disease Activity Score (ASDAS), and study the impact of sex, age, calendar time, disease and symptom duration on ASDAS and ASDAS cut-offs in a large contemporary cohort.
Methods: Data from 2939 patients with axial spondyloarthritis (axSpA) starting their first tumour necrosis factor inhibitor in nine European registries were pooled and analysed. Receiver operating characteristic analyses were performed to identify cut-offs against external criteria.
Objective: Prior incidence estimates of psoriatic arthritis (PsA) vary considerably. We aimed to assess the annual incidence of clinically diagnosed PsA among adults in Sweden in 2014-2016, overall and stratified by age/sex/education/geography, and to investigate potential time trends in incidence in 2006-2018. Use of disease-modifying antirheumatic drugs (DMARDs) during the 2 years after diagnosis was also examined.
View Article and Find Full Text PDFObjectives: To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe.
Methods: Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries.Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0-10), for example, pain ≤2/Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.
Sex differences in patient-reported outcomes and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitors.
Rheumatology (Oxford)
July 2024
Article Synopsis
- The study aimed to explore sex differences in patient-reported outcomes (PROMs) among patients with axial spondyloarthritis (axSpA) starting their first tumor necrosis factor inhibitor (TNFi).
- Data from 15 registries were analyzed, focusing on changes in BASDAI and BASFI scores over 24 months using linear mixed models.
- Results indicated that women reported significantly worse outcomes than men, with the sex differences in scores nearly doubling after 6 months, and baseline characteristics such as HLA-B27 positivity and disease duration helped explain some but not all of the differences.
Article Synopsis
- The study aimed to determine whether the modified 28-joint disease activity index (DAPSA28) or the 28-joint disease activity score with C-reactive protein (DAS28-CRP) is better for monitoring disease activity in psoriatic arthritis (PsA) when the full joint count is unavailable.
- Analysis of real-world data from over 3,000 European patients revealed that at the 6-month mark, DAPSA28 provided similar remission rates to DAPSA, but DAS28-CRP showed significantly higher rates of both remission and response.
- The results suggest that DAPSA28 is preferable to DAS28-CRP when conducting assessments without a full joint count due to the
Parasites are ubiquitous, diverse, and have close interactions with humans and other animals. Despite this, they have not garnered significant interest from forensic scientists, and their utility as indicators in criminal investigations has been largely overlooked. To foster the development of forensic parasitology we explore the utility of parasites as forensic indicators in five broad areas: (i) wildlife trafficking and exploitation, (ii) biological attacks, (iii) sex crimes, (iv) criminal neglect of humans and other animals, and (v) indicators of movement and travel.
View Article and Find Full Text PDFObjective: To study the impact of tumour necrosis factor-α inhibitor (TNFi) therapy on the use of non-steroidal anti inflammatory drugs (NSAIDs) in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) in Iceland.
Method: This registry cohort study used data from the nationwide database on biologics in Iceland (ICEBIO) and the Icelandic Prescription Medicines Register on disease activity, and filled prescriptions for NSAIDs, to study the period from 2 years before to 2 years after initiation of a first TNFi. Five randomly selected individuals from the general population matched on age, sex, and calendar time for each patient served as comparators.
Objective: Emerging research suggests that rheumatoid arthritis (RA) is associated with intestinal dysbiosis. This prospective pilot study evaluates changes in intestinal microbial composition in patients with RA initiating treatment with either methotrexate (MTX) or a tumor necrosis factor inhibitor (TNFi).
Methods: Consecutive patients, fulfilling the 2010 American College of Rheumatology/EULAR classification criteria for RA, who started treatment with either MTX or TNFi delivered a stool sample upon initiation of immunosuppression and 3 months later.
Objective: Ankylosing Spondylitis Disease Activity Score based on C-reactive protein (ASDAS-CRP) is recommended over ASDAS based on erythrocyte sedimentation rate (ASDAS-ESR) to assess disease activity in axial spondyloarthritis (axSpA). Although ASDAS-CRP and ASDAS-ESR are not interchangeable, the same disease activity cut-offs are used for both. We aimed to estimate optimal ASDAS-ESR values corresponding to the established ASDAS-CRP cut-offs (1.
View Article and Find Full Text PDFObjective: To evaluate patient-reported outcomes (PROs) after initiation of tumor necrosis factor inhibitor (TNFi) treatment in European real-world patients with psoriatic arthritis (PsA). Further, to investigate PRO remission rates across treatment courses, registries, disease duration, sex, and age at disease onset.
Methods: Visual analog scale or numerical rating scale scores for pain, fatigue, patient global assessment (PtGA), and the Health Assessment Questionnaire-Disability Index (HAQ-DI) from 12,262 patients with PsA initiating a TNFi in 13 registries were pooled.
Objectives: To compare all-cause mortality and causes of death between patients with psoriatic arthritis (PsA) and the general population in Sweden.
Methods: Adults with at least one main PsA diagnosis (International Classification of Diseases-10: L40.5/M07.
Objective: While considerable focus has been placed on pain due to inflammation in psoriatic arthritis (PsA), less is reported on pain despite inflammation control. Here, we aimed to investigate the occurrence/predictors of persistent pain, including non-inflammatory components, after starting anti-tumour necrosis factor (anti-TNF) therapy.
Method: Bionaïve PsA patients starting a first anti-TNF therapy 2004-2010 were identified (South Swedish Arthritis Treatment Group register; N = 351).
Objective: Women with psoriatic arthritis (PsA) may have reduced tumor necrosis factor inhibitor (TNFi) effectiveness compared to men. We examined sex differences in treatment response and retention rates during 24 months of follow-up among patients with PsA initiating their first TNFi.
Methods: Data from patients with PsA across 13 European Spondyloarthritis Research Collaboration Network registries starting their first TNFi were pooled.
Article Synopsis
- This study aimed to evaluate how effective tumor necrosis factor inhibitors (TNFi) are for patients with axial spondyloarthritis (axSpA), focusing on those in their second or third series of TNFi treatment and why they switched medications (due to lack of efficacy or adverse events).
- Data from 12 European registries was analyzed, showing that 12-month retention rates for second and third TNFi were similar (71%), but six-month remission rates were higher for the second TNFi (23%) compared to the third (16%).
- Patients who discontinued their first TNFi due to adverse events had better remission rates on the second TNFi compared to those who switched due to lack
Article Synopsis
- This report compares treatment recommendations for two types of arthritis, PsA and axSpA, in different European countries.
- Rheumatologists from 15 countries answered a survey, showing that only a few countries fully followed the latest recommendations.
- The findings suggest that some countries might need to change their treatment guidelines to match the newer international ones better.
Article Synopsis
- The study aimed to identify baseline predictors for remission and drug retention in bio-naïve patients with Psoriatic Arthritis (PsA) starting TNF inhibitors, analyzing data from 13 European registries.
- In a pooled cohort of 13,369 patients, results showed that 25% achieved remission and 34% had a moderate response at 6 months, while 63% retained their medication at 12 months.
- Five common baseline predictors, including age, disease duration, sex, CRP levels, and fatigue score, were identified as significant for all three outcomes, suggesting these findings are applicable across different populations.
Introduction: We aimed to compare the proportions of patients with newly diagnosed psoriatic arthritis (PsA) and rheumatoid arthritis (RA) remaining on methotrexate (regardless of other disease-modifying antirheumatic drug (DMARD)-changes), and proportions not having started another DMARD (regardless of methotrexate discontinuation), within 2 years of starting methotrexate, as well as methotrexate effectiveness.
Methods: Patients with DMARD-naïve, newly diagnosed PsA, starting methotrexate 2011-2019, were identified from high-quality national Swedish registers and matched 1:1 to comparable patients with RA. Proportions remaining on methotrexate and not starting another DMARD were calculated.
Objective: Psoriatic arthritis (PsA) prevalence estimates vary across studies; studies based on national data are few. We aimed to estimate the prevalence of clinically diagnosed PsA in Sweden in 2017, overall and stratified by sex, age, education, and geography, and to quantify disease-modifying antirheumatic drug (DMARD) use among those in contact with specialized rheumatology care between 2015 and 2017.
Methods: Individuals who were 18 to 79 years of age, alive and residing in Sweden on December 31, 2017, and had a prior PsA diagnosis were identified from the National Patient Register (NPR) and/or the Swedish Rheumatology Quality Register (SRQ).
Article Synopsis
- The study aimed to analyze the use of newer biologic or targeted synthetic medications (b/tsDMARDs) for psoriatic arthritis in Nordic countries, focusing on their retention rates and effectiveness compared to adalimumab.
- Data was collected from patients starting b/tsDMARDs between 2012 and 2020, revealing that while the uptake of these newer drugs increased until 2018, they were mainly prescribed to patients with previous biologic treatment experiences.
- The results showed that adalimumab had better retention and effectiveness rates in terms of achieving low disease activity when used as a second or third treatment option, suggesting that it may still be the preferred choice for patients.
Climate change and deforestation are causing rainforests to become increasingly fragmented, placing them at heightened risk of biodiversity loss. Invertebrates constitute the greatest proportion of this biodiversity, yet we lack basic knowledge of their population structure and ecology. There is a compelling need to develop our understanding of the population dynamics of a wide range of rainforest invertebrates so that we can begin to understand how rainforest fragments are connected, and how they will cope with future habitat fragmentation and climate change.
View Article and Find Full Text PDF